Significant Ownership of LIGAND PHARMACEUTICALS INC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for LIGAND PHARMACEUTICALS INC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Andrew Reardon - Andrew Reardon, Chief Legal Officer and Secretary
- Manager location
- San Diego, CA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow LIGAND PHARMACEUTICALS INC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from LIGAND PHARMACEUTICALS INC
Significant Ownership of LIGAND PHARMACEUTICALS INC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PTHS | Pelthos Therapeutics Inc. | Common Stock, par value $0.0001 per share | 50% | $145,296,959 | +$7,316,652 | 5,189,177 | +5.3% | Ligand Pharmaceuticals Incorporated | 06 Nov 2025 |
| XOMA | XOMA ROYALTY CORPORATION | Common Stock, par value $0.0075 per share | 47% | $311,622,505 | 8,062,678 | Ligand Pharmaceuticals Incorporated | 27 Apr 2026 |
Schedules 13D/G Reported by LIGAND PHARMACEUTICALS INC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.